GlassScriptPhysician profile
Dominykas Burneikis
NPI 1982082913
$3,771.47
in general payments reported to CMS, 2019-2025
13 companies · $91.63 in 2025
The $91.63 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,037 · 2023: $1,307 · 2024: $335 · 2025: $91.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715 · Travel and Lodging: $19.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.23 |
| Travel and Lodging | $19.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,705.99 | 2022-2024 | Da Vinci Surgical System |
| Medtronic, INC. | $247.82 | 2022-2025 | Interstim |
| Boston Scientific Corporation | $239.89 | 2022-2025 | Spyglass Discover |
| Myriad Genetic Laboratories, INC. | $185.20 | 2023 | Myrisk |
| Abbvie INC. | $113.48 | 2023-2024 | Strattice Reconstructive Tissue Matrix Bps |
| Stryker Corporation | $102.70 | 2023-2024 | Spy-Phi System |
| Astrazeneca Pharmaceuticals LP | $67.95 | 2023-2024 | Andexxa |
| Innovation Technologies INC | $23.47 | 2023 | Irrisept |
| Thd America, INC. | $20.15 | 2024 | |
| Davol INC. | $18.17 | 2023 | |
| Allergan, INC. | $18.01 | 2022 | |
| Hologic Sales and Service, LLC | $14.40 | 2023 | Coolseal Generator |
| Braintree Laboratories, INC. | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominykas Burneikis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.